Full Text | PDF

Theranostics 2020; 10(24):11230-11243. doi:10.7150/thno.45273 This issue Cite

Research Paper

Noninvasive quantification of target availability during therapy using paired-agent fluorescence tomography

Boyu Meng¹, Margaret R. Folaron¹, Rendall R. Strawbridge¹, Negar Sadeghipour², Kimberley S. Samkoe³, Kenneth Tichauer², Scott C. Davis^1✉

1. Thayer School of Engineering, Dartmouth College, Hanover, NH 03755.
2. Biomedical Engineering, Illinois Institute of Technology, Chicago, IL 60616.
3. Geisel School of Medicine, Dartmouth College, Hanover, NH 03755.

✉ Corresponding author: Scott C. Davis, PhD, Thayer School of Engineering, Dartmouth College, Hanover, NH 03755. Phone: (603) 646-9684; Fax: (603) 646-3856; E-mail: scott.c.davisedu.

Abstract

Immuno-oncological treatment strategies that target abnormal receptor profiles of tumors are an increasingly important feature of cancer therapy. Yet, assessing receptor availability (RA) and drug-target engagement, important determinants of therapeutic efficacy, is challenging with current imaging strategies, largely due to the complex nonspecific uptake behavior of imaging agents in tumors. Herein, we evaluate whether a quantitative noninvasive imaging approach designed to compensate for nonspecific uptake, MRI-coupled paired-agent fluorescence tomography (MRI-PAFT), is capable of rapidly assessing the availability of epidermal growth factor receptor (EGFR) in response to one dose of anti-EGFR antibody therapy in orthotopic brain tumor models.

Methods: Mice bearing orthotopic brain tumor xenografts with relatively high EGFR expression (U251) (N=10) or undetectable human EGFR (9L) (N=9) were considered in this study. For each tumor type, mice were either treated with one dose of cetuximab, or remained untreated. All animals were scanned using MRI-PAFT, which commenced immediately after paired-agent administration, and values of RA were recovered using a model-based approach, which uses the entire dynamic sequence of agent uptake, as well as a simplified “snapshot” approach which requires uptake measurements at only two time points. Recovered values of RA were evaluated between groups and techniques. Hematoxylin & eosin (H&E) and immunohistochemical (IHC) staining was performed on tumor specimens from every animal to confirm tumor presence and EGFR status.

Results: In animals bearing EGFR(+) tumors, a significant difference in RA values between treated and untreated animals was observed (RA = 0.24 ± 0.15 and 0.61 ± 0.18, respectively, p=0.027), with an area under the curve - receiver operating characteristic (AUC-ROC) value of 0.92. We did not observe a statistically significant difference in RA values between treated and untreated animals bearing EGFR(-) tumors (RA = 0.18 ± 0.19 and 0.27 ± 0.21, respectively; p = 0.89; AUC-ROC = 0.55), nor did we observe a difference between treated EGFR(+) tumors compared to treated and untreated EGFR(-) tumors. Notably, the snapshot paired-agent strategy quantified drug-receptor engagement within just 30 minutes of agent administration. Examination of the targeted agent alone showed no capacity to distinguish tumors either by treatment or receptor status, even 24h after agent administration.

Conclusions: This study demonstrated that a noninvasive imaging strategy enables rapid quantification of receptor availability in response to therapy, a capability that could be leveraged in preclinical drug development, patient stratification, and treatment monitoring.

Keywords: quantitative molecular imaging, fluorescence tomography, receptor-targeted therapy, antibody treatment monitoring, receptor imaging

Citation styles

©2024 Ivyspring International Publisher. Terms of use